Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Sanofi springs for Protein Sciences
by Rick Mullin
July 17, 2017
| A version of this story appeared in
Volume 95, Issue 29
Sanofi has agreed to buy Protein Sciences, a vaccines manufacturer, for $650 million. Based in Connecticut, Protein Sciences received FDA approval in October for Flublok Quadrivalent, which it touts as the only recombinant protein-based influenza vaccine to be cleared by the agency. “The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg-based vaccine,” says David Loew, head of Sanofi’s vaccines division. Sanofi will pay as much as $100 million more if certain milestones are hit.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X